NeOnc’s NEO100 Brain Tumor Trial Progresses, Keeping a Key Catalyst in Play for Investors

NeOnc Technologies Holdings, Inc. (NTHI) announced an update on their ongoing clinical study.

Study Overview
NeOnc Technologies Holdings, Inc. (NTHI) is running a Phase 2 trial titled “An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma.” The goal is to see if its drug NEO100 can safely help patients whose aggressive brain tumors (grade II or III meningiomas) remain, recur, or keep growing after surgery or other care. This is important because treatment options for these patients are limited and outcomes are often poor, so any signal of benefit could open a new niche in brain cancer therapy.

Intervention/Treatment
The study tests NEO100, a purified form of perillyl alcohol delivered as a drug treatment. Patients self-administer NEO100 four times a day in 28‑day cycles. The aim is to control tumor growth and extend survival while keeping side effects manageable, creating a potential targeted option in a difficult brain tumor segment.

Study Design
This is an interventional Phase 2 trial with a single treatment group; there is no random assignment to different arms. All enrolled patients receive NEO100, and there is no placebo or masking, meaning both doctors and patients know the drug being used. The main purpose is treatment: to track safety, drug levels in the body, and early signs of effectiveness such as tumor response and disease control.

Study Timeline
The study was first submitted on August 20, 2021, signaling the formal launch of the program. It is currently listed as “recruiting,” indicating active enrollment and no primary completion date yet reported. The most recent update was submitted on December 18, 2025, which shows the sponsor is maintaining the trial and suggests ongoing data collection and operational progress. The estimated final completion date has not been disclosed but will be key for when investors can expect top-line data.

Market Implications
For NTHI, continued recruitment and a fresh December 2025 update support the view that the program is alive, funded, and operational, which can help underpin investor confidence in the company’s pipeline. High‑grade meningioma is a narrow but high‑need niche; even modest positive data could support premium pricing and potential partnering interest, especially if safety looks clean. In the short term, the update alone is unlikely to drive a major re‑rating, but it lowers perceived execution risk and keeps a clinical catalyst on the horizon. Investors will watch future readouts closely and compare NEO100’s performance with other emerging brain tumor approaches, including targeted drugs and novel delivery methods from larger oncology players. Any strong efficacy signals could shift sentiment quickly, potentially lifting NTHI’s valuation as a focused, early‑stage brain cancer story.

The NEO100 meningioma study remains ongoing with recent updates filed, and further details are available on the ClinicalTrials.gov portal.

To learn more about NTHI’s potential, visit the NeOnc Technologies Holdings, Inc. drug pipeline page.